The New Agents Committee (NAC) funding scheme provides a one-step process for selecting new anti-cancer treatments and diagnostics and taking them into early clinical trials. The NAC was set up by Cancer Research UK's Drug Development Office (DDO). The NAC meets four times a year and comprises clinicians expert in early clinical trials of novel agents as well as other experts in drug development.

NAC trial grants are funded for two years. Requests for longer trial grant funding will be considered and may be awarded if justified by the study design. Applications will only be accepted from individuals based in UK academic institutions. For NAC Trial Grants - funding of £50,000 per annum is available. Requests for funding above this level will be considered and amounts in excess of £50k per annum may be awarded if justified by the study design.

DDO project proposals can be made by individuals based in academic institutions and industry collaborators worldwide. A project budget and DDO staff to manage the development process are allocated for the duration required to develop the agent and undertake the trial.

Further information and details of how to apply can be found at the link below. The closing date for applications is 20 April 2012.

Cancer Research UK